Presented positive preclinical data for the solid tumor program at three scientific conferences; data suggest exogenous ultra-high concentration gaseous NO can trigger anti-tumor immunity
... | June 16, 2021
Submitted first premarket approval application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn ; Company preparing for... | June 10, 2021
Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the...